Shareholder rights law firm Robbins LLP has launched an investigation into Blaize Holdings, Inc. (NASDAQ: BZAI) to determine if company officers and directors violated securities laws or breached fiduciary duties. The probe follows a sharp decline in Blaize’s stock price on August 14, 2026, triggered by the company’s second quarter 2026 earnings release. In the filing, management drastically reduced its full-year 2026 revenue guidance from $130 million to a range of $40 million to $43 million, citing customer rollout delays and issues with collecting payments.

The stock price drop was compounded by a downgrade from DA Davidson, which cut its target price from $3 to $1 and changed its rating from Buy to Neutral. This new development adds to ongoing legal scrutiny of Blaize, as shareholder rights firms Robbins LLP, Rosen Law Firm, Glancy Prongay Wolke & Rotter LLP, and Bragar Eagel & Squire, P.C. are already urging investors to secure representation ahead of the October 5, 2026, deadline to serve as lead plaintiff in a separate securities class action.

Existing Class Action Context

The existing lawsuit alleges that Blaize made materially false and misleading statements regarding its business operations and financial condition, specifically focusing on a $50 million transaction with NeoTensr. The legal action stems from a short seller report by Pelican Way Research published on April 28, 2026, which questioned the legitimacy of the NeoTensr deal. The report alleged that Blaize artificially boosted its share price through a bogus deal with a four-month-old counterparty whose website featured products that appeared to be photoshopped.

That disclosure caused Blaize’s stock to fall more than 12%, closing at $1.90 on April 28, 2026. The lawsuit claims Blaize improperly recognized revenue and created an appearance of growth through transactions with entities deemed unequipped to conduct meaningful business. Investors who purchased shares between July 18, 2025, and April 28, 2026, may be entitled to compensation without out-of-pocket fees through a contingency fee arrangement.

Key Dates and Metrics

Investor Contact Information

To join the class action or provide information regarding the new investigation, investors can contact Phillip Kim, Esq., at Rosen Law Firm toll-free at 866-767-3653 or via email at case@rosenlegal.com . Alternatively, investors may contact attorney Aaron Dumas, Jr., at Robbins LLP by calling (800) 350-6003 or emailing adumas@robbinsllp.com .

Glancy Prongay Wolke & Rotter LLP has also issued reminders regarding the upcoming deadline. Investors interested in this firm can contact Charles Linehan, Esq., via email at shareholders@glancylaw.com , by telephone at 310-201-9150, or toll-free at 888-773-9224. Bragar Eagel & Squire, P.C. has issued an alert regarding the case; investors can contact Litigation Partner Brandon Walker or Melissa Fortunato by email at investigations@bespc.com or by telephone at (212) 355-4648.

Both firms emphasize that no class has been certified yet, meaning investors are not represented by counsel unless they retain one. Shareholders may also remain absent class members, with their ability to share in any potential future recovery not dependent on serving as lead plaintiff.

What the Numbers Show

The convergence of two distinct negative catalysts highlights mounting pressure on Blaize Holdings. First, the April 2026 short seller report triggered a more than 12% single-day stock decline, underscoring market skepticism regarding the $50 million NeoTensr deal. Second, the August 2026 earnings release revealed a severe contraction in expected performance, with full-year revenue guidance slashed from $130 million to a maximum of $43 million. This represents a potential reduction of nearly 67% from the initial outlook, driven by operational execution failures rather than just accounting disputes. The simultaneous legal scrutiny over past transactions and current operational viability suggests a broad-based challenge to the company’s valuation narrative.

Blaize Holdings, Inc. (NASDAQ: BZAI) faces a securities investigation after slashing its full-year revenue guidance by approximately 68%. The company lowered its outlook from $130 million to a range of $40–$43 million on August 13, 2026, citing commercial opportunities that "did not materialize as expected" and higher memory costs. Shares traded below $0.64 on August 14, more than 65% below the May public offering price of $1.85.

Johnson Fistel, PLLP is investigating whether Blaize or certain executive officers violated federal securities laws in connection with revenue guidance, customer agreements, purchase orders, accounts receivable, and pipeline metrics. The firm is seeking investors who suffered losses to participate in the investigation.

Customer Deal Risks

The guidance cut follows disclosures regarding significant risks in key customer relationships. Blaize’s Form 10-Q revealed that Starshine issued only one $10.4 million purchase order, of which $8.8 million remained unpaid. This receivable was transferred to Blaize’s wholly owned Chinese subsidiary, with a third-party agent pursuing payment. Blaize fully reserved the receivable, warning of substantial risk that collection efforts might fail. Management stated it would not engage further with Starshine unless the outstanding balance was paid.

Regarding NeoTensr, Blaize disclosed that a previous $23.8 million receivable was paid in full, driving second-quarter revenue momentum. However, an April 2026 agreement for up to $50 million remained subject to purchase orders. As of August 13, NeoTensr had issued only one $13.7 million purchase order. On August 7, the agreement was amended to establish a firm contract with a minimum purchase commitment, known as a take-or-pay arrangement.

Pipeline Metric Changes

Blaize announced it no longer considers its previously reported pipeline metrics to be key business metrics. The company determined these figures were "not as closely connected with future revenue as previously expected" and stated it did not expect to present them in future filings.

What the Numbers Show

The divergence between Blaize’s initial $130 million guidance and the revised $40–$43 million midpoint highlights a severe disconnect between planned commercial cadence and actual execution. With only $13.7 million in confirmed purchase orders from NeoTensr against a $50 million potential agreement, and a fully reserved $8.8 million receivable from Starshine, the company’s near-term revenue visibility appears heavily dependent on the new take-or-pay structure with NeoTensr rather than organic order inflow.